newsfilter
← Latest News
GlobeNewswire·

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical